As it contemplates a partnership and an initial public offering, oncology drug developer Aragon Pharmaceuticals Inc. has turned to private investors for a $42 million Series C round of funding that could provide flexibility for both actions.
The Topspin Fund, which invests on behalf of individuals including billionaire hedge fund founder Jim Simons of Renaissance Technologies, participated alongside Aragon’s existing investors. The same individuals, including longtime Pittway Corp. and Honeywell International Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?